Zuo W M, Pratt R E, Heusser C H, Bews J P, de Gasparo M M, Dzau V J
Division of Cardiovascular Medicine, Stanford University School of Medicine, Calif.
Hypertension. 1992 Mar;19(3):249-54. doi: 10.1161/01.hyp.19.3.249.
We have identified and characterized an anti-human renin monoclonal antibody R1-20-5 that is selective for human active renin. R1-20-5 binds active renin with a dissociation constant (Kd) of 2.5 x 10(-7) M/l and inhibits renin enzymatic activity with an inhibitory constant (IC50) of 1.4 x 10(-8) M/l. R1-20-5 competes with a synthetic renin inhibitor for binding with renin, demonstrating further that it is binding to or close to the active site. This antibody does not bind prorenin in human plasma or recombinant prorenin expressed by L-929 fibroblasts transfected with human renin gene. Furthermore, trypsin activation of prorenin resulted in immunoreactivity of the activated prorenin toward the antibody. In addition, an immunoaffinity column of R1-20-5 coupled to Sepharose retained active renin but had a low affinity for prorenin. A sensitive and rapid solid phase radioimmunoassay for active renin was developed using a "sandwich" technique employing R1-20-5 and a second non-active site-directed monoclonal antibody to human renin. Renin levels in human plasma samples were determined by the standard enzymatic assay, and by the direct radioimmunoassay for active renin, before and after trypsin activation. Trypsin treatment of plasma resulted in parallel increases in both the plasma renin enzymatic activity and in the plasma active renin concentration as measured by the direct radioimmunoassay. Overall, plasma immunoreactive active renin concentration correlated significantly with plasma renin enzymatic activity (r = 0.96, p less than 0.001). In summary, the monoclonal antibody R1-20-5 is selective for human active renin and should be a very useful tool for studies of the active enzyme in humans.
我们已经鉴定并表征了一种抗人肾素单克隆抗体R1-20-5,它对人活性肾素具有选择性。R1-20-5与活性肾素结合的解离常数(Kd)为2.5×10(-7)M/l,抑制肾素酶活性的抑制常数(IC50)为1.4×10(-8)M/l。R1-20-5与一种合成肾素抑制剂竞争与肾素的结合,进一步证明它与活性位点结合或接近活性位点。该抗体不与人血浆中的肾素原或用人肾素基因转染的L-929成纤维细胞表达的重组肾素原结合。此外,肾素原的胰蛋白酶激活导致活化的肾素原对该抗体产生免疫反应性。另外,偶联到琼脂糖上的R1-20-5免疫亲和柱保留活性肾素,但对肾素原的亲和力较低。利用“夹心”技术,采用R1-20-5和第二种针对人肾素的非活性位点定向单克隆抗体,开发了一种用于活性肾素的灵敏、快速的固相放射免疫测定法。在胰蛋白酶激活前后,通过标准酶测定法和活性肾素直接放射免疫测定法测定人血浆样品中的肾素水平。血浆的胰蛋白酶处理导致血浆肾素酶活性以及通过直接放射免疫测定法测得的血浆活性肾素浓度同时平行增加。总体而言,血浆免疫反应性活性肾素浓度与血浆肾素酶活性显著相关(r = 0.96,p小于0.001)。总之,单克隆抗体R1-20-5对人活性肾素具有选择性,应该是研究人体内活性酶的非常有用的工具。